Publications
-
Sanchez-Guixe E, Muiños F, Pinheiro-Santin M, González-Huici V, Rodriguez-Hernandez CJ, Avgustinova A, Lavarino C, González- Pérez A, Mora J and López-Bigas N.
Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues
CANCER DISCOVERY . 14(6): 953-964. Number of citations: 6
-
Caballero R, Pasten A, Giménez C, Raquel Rodriguez Baladon, Carmona-Jiménez RM, Mora J, Valls-Esteve A, Lustig P, Lombardini F, Balsells S and Krauel L.
Beyond Needles: Pioneering Pediatric Care with Virtual Reality (VR) for TIVAD Access in Oncology
Cancers . 16(12): . Number of citations: 2
-
Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.
Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects
Frontiers in oncology . 14: 1380917-1380917.
-
Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy
Cancers . 16(9): . Number of citations: 1
-
Pasten A, Salvador-Alarcon C, Mora J, Martín Gimenez MP, Carrasco-Torrents R and Krauel L.
Current Status of Fertility Preservation in Pediatric Oncology Patients
CHILDREN-BASEL . 11(5): . Number of citations: 2
-
Mora J, Modak S, Kinsey J, Ragsdale CE and Lazarus HM.
GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma
INTERNATIONAL JOURNAL OF CANCER . 154(8): 1340-1364. Number of citations: 10
-
Villasante A, Corominas J, Alcon C, Garcia-Lizarribar A, Mora J, Lopez-Fanarraga M and Samitier J.
Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model
Cancers . 16(5): . Number of citations: 1
-
Llurba E, Crispi F, Crovetto F, Youssef L, Delgado JL, Puig I, Mora J, Krofta L, Mackova K, Martinez-Varea A, Tubau A, Ruiz-Llobet A, Paya A, Prat M, Chantraine F, Comas C, Kajdy A, Lopez-Tinajero MF, Figueras-Retuerta F and Gratacós E.
Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study
BMJ Open . 14(3): . Number of citations: 5
-
Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G.
Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma
PEDIATRIC BLOOD & CANCER . 71(1): . Number of citations: 4
-
Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
Cancers . 15(19): . Number of citations: 12